Table of Contents Author Guidelines Submit a Manuscript
International Journal of Rheumatology
Volume 2014, Article ID 926836, 9 pages
http://dx.doi.org/10.1155/2014/926836
Review Article

HBV Reactivation in Patients Treated with Antitumor Necrosis Factor-Alpha (TNF-α) Agents for Rheumatic and Dermatologic Conditions: A Systematic Review and Meta-Analysis

1Division of Rheumatology, Misericordia e Dolce Hospital, Via Cavour 87/89, 59100 Prato, Italy
2Section of Hygiene, Institute of Public Health, Department of Public Health, Università Cattolica del Sacro Cuore, L.go F.Vito 1, 00168 Rome, Italy
3Translational Research Unit, Department of Epidemiology and Preclinical Research, INMI, Via Portuense 292, 00149 Rome, Italy
4Rheumatology Unit, Interdisciplinary Department of Medicine, University of Bari, Piazza Giulio Cesare 1, 70124 Bari, Italy
5Dermatology Clinic/ASF Department of Surgery and Translational Medicine, University of Florence, Via Lorenzo Il Magnifico 104, 50129 Florence, Italy
6Section of Infectious Diseases, Department of Internal Medicine, Second University of Naples, Via S. Pansini 5, 80131 Naples, Italy

Received 25 March 2014; Revised 26 May 2014; Accepted 11 June 2014; Published 7 July 2014

Academic Editor: Luis R. Espinoza

Copyright © 2014 Fabrizio Cantini et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Bernatsky, Y. Habel, and E. Rahme, “Observational studies of infections in rheumatoid arthritis: a metaanalysis of tumor necrosis factor antagonists,” Journal of Rheumatology, vol. 37, no. 5, pp. 928–931, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. J. B. Galloway, K. L. Hyrich, L. K. Mercer et al., “Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly,” Rheumatology, vol. 50, no. 1, pp. 124–131, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. G. H. W. Wong and D. V. Goeddel, “Tumor necrosis factors α and β inhibit virus replication and synergize with interferons,” Nature, vol. 323, no. 6091, pp. 819–822, 1986. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Mestan, W. Digel, S. Mittnacht et al., “Antiviral effects of recombinant tumour necrosis factor in vitro,” Nature, vol. 323, no. 6091, pp. 816–819, 1986. View at Publisher · View at Google Scholar · View at Scopus
  5. D. Ganem and A. M. Prince, “Hepatitis B virus infection—natural history and clinical consequences,” The New England Journal of Medicine, vol. 350, no. 11, pp. 1118–1129, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. L. G. Guidotti, K. Ando, M. V. Hobbs et al., “Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 9, pp. 3764–3768, 1994. View at Publisher · View at Google Scholar · View at Scopus
  7. L. G. Guidotti, T. Ishikawa, M. V. Hobbs, B. Matzke, R. Schreiber, and F. V. Chisari, “Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes,” Immunity, vol. 4, no. 1, pp. 25–36, 1996. View at Publisher · View at Google Scholar · View at Scopus
  8. WHO, “Hepatitis B,” Fact Sheet 204, 2014, http://www.who.int/mediacentre/factsheets/fs204/en/index.html. View at Google Scholar
  9. G. Raimondo, T. Pollicino, I. Cacciola, and G. Squadrito, “Occult hepatitis B virus infection,” Journal of Hepatology, vol. 46, no. 1, pp. 160–170, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. R. Pérez-Alvarez, C. Díaz-Lagares, F. García-Hernández et al., “Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases,” Medicine, vol. 90, no. 6, pp. 359–371, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. R. Caporali, F. Bobbio-Pallavicini, F. Atzeni et al., “Safety of tumor necrosis factor α blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases,” Arthritis Care and Research, vol. 62, no. 6, pp. 749–754, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. N. Cassano, V. Mastrandrea, M. Principi et al., “Anti-tumor necrosis factor treatment in occult hepatitis B virus infection: a retrospective analysis of 62 patients with psoriatic disease,” Journal of Biological Regulators and Homeostatic Agents, vol. 25, no. 2, pp. 285–289, 2011. View at Google Scholar · View at Scopus
  13. C. Charpin, S. Guis, P. Colson et al., “Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients,” Arthritis Research and Therapy, vol. 11, no. 6, article R179, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. Y. J. Kim, S.-C. Bae, Y.-K. Sung et al., “Possible reactivation of potential hepatitis B virus occult infection by tumor necrosis factor-α blocker in the treatment of rheumatic diseases,” The Journal of Rheumatology, vol. 37, no. 2, pp. 346–350, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Lan, Y. Chen, T. Hsieh et al., “Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy,” Annals of the Rheumatic Diseases, vol. 70, no. 10, pp. 1719–1725, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Mori, “Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugs,” Modern Rheumatology, vol. 21, no. 6, pp. 621–627, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. H. H. Ryu, E. Y. Lee, K. Shin et al., “Hepatitis B virus reactivation in rheumatoid arthritis and ankylosing spondylitis patients treated with anti-TNFα agents: a retrospective analysis of 49 cases,” Clinical Rheumatology, vol. 31, no. 6, pp. 931–936, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Tamori, T. Koike, H. Goto et al., “Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts,” Journal of Gastroenterology, vol. 46, no. 4, pp. 556–564, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. Y. Urata, R. Uesato, D. Tanaka et al., “Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients,” Modern Rheumatology, vol. 21, no. 1, pp. 16–23, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. D. Vassilopoulos, A. Apostolopoulou, E. Hadziyannis et al., “Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection,” Annals of the Rheumatic Diseases, vol. 69, no. 7, pp. 1352–1355, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Liberati, D. G. Altman, J. Tetzlaff et al., “The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration,” Italian Journal of Public Health, vol. 6, no. 4, pp. 354–391, 2009. View at Google Scholar · View at Scopus
  22. A. Stuart, J. K. Ord, S. F. Arnold, A. O’Hagan, and M. G. Kendall, Kendall’s Advanced Theory of Statistics, Edward Arnold, London, UK, 6th edition, 1994.
  23. R. DerSimonian and N. Laird, “Meta-analysis in clinical trials,” Controlled Clinical Trials, vol. 7, no. 3, pp. 177–188, 1986. View at Publisher · View at Google Scholar · View at Scopus
  24. J. P. T. Higgins, S. G. Thompson, J. J. Deeks, and D. G. Altman, “Measuring inconsistency in meta-analyses,” British Medical Journal, vol. 327, no. 7414, pp. 557–560, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. J. P. T. Higgins, S. G. Thompson, and D. J. Spiegelhalter, “A re-evaluation of random-effects meta-analysis,” Journal of the Royal Statistical Society A: Statistics in Society, vol. 172, no. 1, pp. 137–159, 2009. View at Publisher · View at Google Scholar · View at MathSciNet · View at Scopus
  26. C. H. Roux, O. Brocq, V. Breuil, C. Albert, and L. Euller-Ziegler, “Safety of anti-TNF-α therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis,” Rheumatology, vol. 45, no. 10, pp. 1294–1297, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Zingarelli, P. Airò, M. Frassi, C. Bazzani, M. Scarsi, and M. Puoti, “Prophylaxis and therapy of HBV infection in 20 patients treated with disease modifying antirheumatic drugs or with biological agents for rheumatic diseases,” Reumatismo, vol. 60, no. 1, pp. 22–27, 2008. View at Google Scholar · View at Scopus
  28. S. J. Chung, J. K. Kim, M. C. Park, Y. B. Park, and Lee. S. K., “Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy,” Journal of Rheumatology, vol. 36, no. 11, pp. 2416–2420, 2009. View at Publisher · View at Google Scholar
  29. C. Fotiadou, E. Lazaridou, and D. Ioannides, “Safety of anti-tumour necrosis factor-α agents in psoriasis patients who were chronic hepatitis B carriers: a retrospective report of seven patients and brief review of the literature,” Journal of the European Academy of Dermatology and Venereology, vol. 25, no. 4, pp. 471–474, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. F. Prignano, F. Ricceri, L. Pescitelli, F. Zanieri, and T. Lotti, “Tumour necrosis factor-α antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patients,” British Journal of Dermatology, vol. 164, no. 3, pp. 645–647, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Kato, T. Atsumi, T. Kurita et al., “Hepatitis B virus reactivation by immunosuppressive therapy in patients with autoimmune diseases: risk analysis in hepatitis B surface antigen-negative cases,” The Journal of Rheumatology, vol. 38, no. 10, pp. 2209–2214, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. Y.-T. Cho, C.-H. Chen, H.-Y. Chiu, and T.-F. Tsai, “Use of anti-tumor necrosis factor-α therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: a case series in Taiwan,” Journal of Dermatology, vol. 39, no. 3, pp. 269–273, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. A. R. Giardina, D. Ferraro, F. Ciccia et al., “No detection of occult HBV-DNA in patients with various rheumatic diseases treated with anti-TNF agents: a two-year prospective study,” Clinical and Experimental Rheumatology, vol. 31, no. 1, pp. 25–30, 2013. View at Google Scholar · View at Scopus
  34. R. Laurenti, F. Giovannangeli, E. Gubinelli et al., “Long-term safety of anti-TNF adalimumab in HBc antibody-positive psoriatic arthritis patients: a retrospective case series of 8 patients,” Clinical and Developmental Immunology, vol. 2013, Article ID 410521, 5 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. R. Navarro, E. Vilarrasa, P. Herranz et al., “Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting,” The British Journal of Dermatology, vol. 168, no. 3, pp. 609–616, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. T. Nishida, N. Hiramatsu, M. Mizuki et al., “Managing hepatitis B virus carriers with systemic chemotherapy or biologic therapy in the outpatient clinic,” Hepatology Research, vol. 43, no. 4, pp. 339–346, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. R. Stasi, A. Sarpatwari, J. B. Segal et al., “Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review,” Blood, vol. 113, no. 6, pp. 1231–1240, 2009. View at Publisher · View at Google Scholar · View at Scopus